In vivo, using the subcutaneous MB49 bladder cancer model, HSV5-15 virus expressing both the cytokine and TLR agonist ...

Dublin, Aug. 22, 2024 (GLOBE NEWSWIRE) -- The "Oncolytic Virus Therapy Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering.

Oncolytic virus (OV)-based immunotherapy has ... augmenting the immune response against cancer. The success of OV therapy is ...

CF33-hNIS has gained FDA orphan drug designation for the treatment of cholangiocarcinoma and is currently being evaluated in ...

Daiichi Sankyo has launched its oncolytic virus therapy Delytact in Japan – its first world market – as a treatment for malignant glioma, an aggressive form of brain cancer.

Replimune's cash runway supports its accelerated approval and phase 3 trial. See why I think REPL's current low stock price ...

The global cancer gene therapy market is set for significant expansion, with projections indicating a robust compound annual ...

In a captivating Genomic Press Interview published in the peer-reviewed journal Genomic Psychiatry, Professor Mayana Zatz of ...

The first documented use of NDV for human cancer therapy was reported in 1964 by ... such as H-Ras and Rac1 have been shown to mediate oncolytic specificity in certain systems.

TILT Biotherapeutics’ oncolytic viruses enable solid tumor T cell therapy and checkpoint-inhibiting antibodies. T cell therapies, in which white blood cells are manipulated and propagated in the ...

Newcastle disease virus (NDV) is an avian paramyxovirus, which has been demonstrated to possess significant oncolytic activity against mammalian cancers. This review summarizes the research ...